Fannie Mae 'AAA/A-1+' Sr. Debt Rating Affirmed; Other Ratings Lowered, On CreditWatch Negative Aug 08

  • ID: 1930225
  • August 2008
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Aug. 26, 2008--Standard & Poor's Ratings Services said today that it affirmed its 'AAA/A-1+' senior unsecured debt rating on Fannie Mae with a stable outlook. At the same time, we lowered our risk-to-the-government standalone issuer credit rating on Fannie Mae to 'A-' from 'A', the subordinated debt rating to 'BBB+' from 'A-', and the preferred stock rating to 'BBB-' from 'A-'. All the ratings we lowered are also placed on CreditWatch Negative. "The affirmation of the long-term 'AAA' and short-term 'A-1+' senior unsecured debt ratings reflect our expectation of continued government support for the viability of Fannie Mae and its senior unsecured debt, as represented in the Treasury's Economic Stimulus Plan released earlier this year,"...

Companies mentioned in this report are:
- Fannie Mae

Action: Affirmed
Action: Downgraded
Action: On CreditWatch:Negative

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Fannie Mae

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.